Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$58.65+0.77 (+1.33%)
Close on Nov 18, 2026Market cap $3.00BP/E 139.6Yield –
Vericel free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vericel's free cash flow for the twelve months ending Jun 30, 2026 was $61.66M. For fiscal 2025 it was $24.75M. The highest annual figure on record is $24.75M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.75M | – |
| FY2024 | Dec 31, 2024 | -$5.81M | -138.0% |
| FY2023 | Dec 31, 2023 | $15.30M | +51.6% |
| FY2022 | Dec 31, 2022 | $10.09M | -52.2% |
| FY2021 | Dec 31, 2021 | $21.13M | +41.3% |
| FY2020 | Dec 31, 2020 | $14.95M | – |
| FY2019 | Dec 31, 2019 | -$9.80M | – |
| FY2018 | Dec 31, 2018 | -$3.09M | – |
| FY2017 | Dec 31, 2017 | -$14.69M | – |
| FY2016 | Dec 31, 2016 | -$21.31M | – |
| FY2015 | Dec 31, 2015 | -$15.77M | – |
| FY2014 | Dec 31, 2014 | -$26.24M | – |
| FY2013 | Dec 31, 2013 | -$19.98M | – |
| FY2012 | Dec 31, 2012 | -$29.82M | – |
| FY2010 | Jun 30, 2010 | -$15.21M | – |
| FY2009 | Jun 30, 2009 | -$13.84M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.26M | +17503.7% |
| Q1 FY2026 | Mar 31, 2026 | $15.13M | – |
| Q4 FY2025 | Dec 31, 2025 | $12.83M | +51.7% |
| Q3 FY2025 | Sep 30, 2025 | $19.45M | – |
| Q2 FY2025 | Jun 30, 2025 | $81.00K | -95.4% |
| Q1 FY2025 | Mar 31, 2025 | -$7.61M | – |
| Q4 FY2024 | Dec 31, 2024 | $8.46M | +275.6% |
| Q3 FY2024 | Sep 30, 2024 | -$9.23M | -1637.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.77M | -70.4% |
| Q1 FY2024 | Mar 31, 2024 | -$6.82M | -205.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.25M | -61.5% |
| Q3 FY2023 | Sep 30, 2023 | $600.00K | -77.7% |
| Q2 FY2023 | Jun 30, 2023 | $6.00M | +416.4% |
| Q1 FY2023 | Mar 31, 2023 | $6.45M | +1565.9% |
| Q4 FY2022 | Dec 31, 2022 | $5.85M | -38.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.69M | +129.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.16M | -56.2% |
| Q1 FY2022 | Mar 31, 2022 | $387.00K | -95.0% |
| Q4 FY2021 | Dec 31, 2021 | $9.56M | -6.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.17M | -72.1% |
| Q2 FY2021 | Jun 30, 2021 | $2.65M | – |
| Q1 FY2021 | Mar 31, 2021 | $7.74M | +95.1% |
| Q4 FY2020 | Dec 31, 2020 | $10.27M | +268.1% |
| Q3 FY2020 | Sep 30, 2020 | $4.20M | -38.8% |
| Q2 FY2020 | Jun 30, 2020 | -$3.49M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.97M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.79M | +37.1% |
| Q3 FY2019 | Sep 30, 2019 | $6.86M | +670.0% |
| Q2 FY2019 | Jun 30, 2019 | -$19.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$78.00K | -135.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.03M | +1653.4% |
| Q3 FY2018 | Sep 30, 2018 | $891.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.24M | – |
| Q1 FY2018 | Mar 31, 2018 | $221.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $116.00K | – |
See a number that looks wrong?